Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review)
暂无分享,去创建一个
A. Bramanti | P. Bramanti | E. Cavalli | P. Fagone | F. Nicoletti | A. Giordano | Y. Shoenfeld | A. Tchorbanov | R. Ciurleo | C. Belizna
[1] Z. Amoura,et al. High frequency of antiphospholipid antibodies in critically ill COVID‐19 patients: a link with hypercoagulability? , 2020, Journal of internal medicine.
[2] V. Schini-Kerth,et al. COVID-19 Related Coagulopathy: A Distinct Entity? , 2020, Journal of clinical medicine.
[3] R. Schneider,et al. Clinically significant anticardiolipin antibodies associated with COVID-19 , 2020, Journal of Critical Care.
[4] S. Zayet,et al. Acute Cerebral Stroke with Multiple Infarctions and COVID-19, France, 2020 , 2020, Emerging infectious diseases.
[5] M. Murad,et al. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta‐Analysis , 2020, Journal of the American Geriatrics Society.
[6] P. Demelo-Rodríguez,et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism , 2020, Thrombosis Research.
[7] M. Luppi,et al. More on: ‘COVID‐19 coagulopathy in Caucasian patients’ , 2020, British journal of haematology.
[8] O. Godefroy,et al. COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies? , 2020, Revue Neurologique.
[9] S. Sivapalaratnam,et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 , 2020, The New England journal of medicine.
[10] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[11] P. Bramanti,et al. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies , 2020, Autoimmunity Reviews.
[12] Hongzhou Lu,et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. , 2020, Bioscience trends.
[13] S. Farmer,et al. Characteristics of ischaemic stroke associated with COVID-19 , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[14] S. Laufer,et al. Candidate drugs against SARS-CoV-2 and COVID-19 , 2020, Pharmacological Research.
[15] John D. Lambris,et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 , 2020, Clinical Immunology.
[16] Thomas J Oxley,et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.
[17] K. Maiese. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment , 2020, Current neurovascular research.
[18] Nils Kucher,et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.
[19] John D Lambris,et al. Complement as a target in COVID-19? , 2020, Nature Reviews Immunology.
[20] B. Drénou,et al. Lupus anticoagulant is frequent in patients with Covid‐19 , 2020, Journal of Thrombosis and Haemostasis.
[21] V. Lougaris,et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.
[22] Koichi Yuki,et al. COVID-19 pathophysiology: A review , 2020, Clinical Immunology.
[23] A. Huisman,et al. Thromboembolic events and apparent heparin resistance in patients infected with SARS‐CoV‐2 , 2020, International journal of laboratory hematology.
[24] David Berlin,et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.
[25] Yutao Guo,et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.
[26] Wei Zhou,et al. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor , 2020, Pharmacological Research.
[27] Carol H. Yan,et al. Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptoms , 2020, International forum of allergy & rhinology.
[28] Q. Ye,et al. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.
[29] R. Kahwash,et al. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? , 2020, Circulation.
[30] Xiaowei Yan,et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.
[31] N. Vaninov. In the eye of the COVID-19 cytokine storm , 2020, Nature Reviews Immunology.
[32] D. D'cruz,et al. An update on the management of antiphospholipid syndrome , 2020, Therapeutic advances in musculoskeletal disease.
[33] Dengju Li,et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.
[34] M. Cascella,et al. Features, Evaluation and Treatment Coronavirus (COVID-19) , 2020 .
[35] Tian Huang,et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.
[36] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[37] H. Rothan,et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.
[38] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[39] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[40] Weier Wang,et al. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China , 2020, Journal of medical virology.
[41] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[42] N. Linton,et al. The Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020 , 2020, Journal of clinical medicine.
[43] K. Shuford,et al. Design and Catalyzed Activation of Tak-242 Prodrugs for Localized Inhibition of TLR4-Induced Inflammation. , 2020, ACS medicinal chemistry letters.
[44] G. Espinosa,et al. Plasma exchange in catastrophic antiphospholipid syndrome. , 2019, Presse medicale.
[45] J. Schneider,et al. Antiphospholipid Antibodies: Cognitive and Motor Decline, Neuroimaging and Neuropathology , 2019, Neuroepidemiology.
[46] S. Testa,et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. , 2018, Thrombosis research.
[47] M. García-Carrasco,et al. Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant) , 2018, Current Rheumatology Reports.
[48] A. Tincani,et al. The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. , 2018, Journal of autoimmunity.
[49] D. Raoult,et al. Thrombosis and antiphospholipid antibody syndrome during acute Q fever , 2017, Medicine.
[50] Md. Asiful Islam,et al. Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies. , 2017, Current vascular pharmacology.
[51] Y. Shoenfeld,et al. Diagnosis and management of catastrophic antiphospholipid syndrome , 2017, Expert review of hematology.
[52] 朱剑,et al. Antiphospholipid syndrome , 2017 .
[53] M. García-Carrasco,et al. The role of infectious diseases in the catastrophic antiphospholipid syndrome. , 2015, Autoimmunity reviews.
[54] N. Beglova,et al. An A1–A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome , 2015, The FEBS journal.
[55] D. Sblattero,et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. , 2014, Blood.
[56] N. Beglova,et al. Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome. , 2014, Blood.
[57] R. Cervera,et al. Diagnosis and classification of the antiphospholipid syndrome. , 2014, Journal of autoimmunity.
[58] G. Espinosa,et al. Catastrophic antiphospholipid syndrome triggered by fulminant disseminated herpes simplex infection in a patient with systemic lupus erythematosus , 2012, Lupus.
[59] P. Fagone,et al. mTOR as a multifunctional therapeutic target in HIV infection. , 2011, Drug discovery today.
[60] A. De Biasio,et al. A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI/Antibody Complexes Implicated in Antiphospholipid Syndrome , 2010, PloS one.
[61] G. Espinosa,et al. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. , 2010, Autoimmunity reviews.
[62] A. De Biasio,et al. Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. , 2010, Structure.
[63] F. Nicoletti,et al. Inhibition of human immunodeficiency virus (HIV‐1) infection in human peripheral blood leucocytes‐SCID reconstituted mice by rapamycin , 2009, Clinical and experimental immunology.
[64] E. Mazzon,et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. , 2007, Clinical immunology.
[65] C. Feighery,et al. Circulating levels of β2-glycoprotein I in thrombotic disorders and in inflammation , 2006, Lupus.
[66] B. Chong,et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. , 1990, Australian and New Zealand journal of medicine.
[67] R. Searles,et al. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. , 1989, The Journal of rheumatology.
[68] E. Lazartigues,et al. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[69] E. Harris,et al. The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.